Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
- Combining Systemic Therapies for Patients with Advanced Liver Cancer
(Posted: 03/20/2012) - In this phase III trial, patients with unresectable, locally advanced or metastatic primary liver cancer who have good liver function (Child-Pugh score A) will receive sorafenib and be randomly assigned to also receive either doxorubicin or no additional therapy.
- Exploring the Anticancer Potential of Valproic Acid in Advanced Thyroid Cancer
(Posted: 03/07/2012) - In this trial, patients with advanced thyroid cancers of follicular cell origin whose tumors are not sensitive to radioactive iodine therapy will take valproic acid for 10 weeks and then undergo a radioactive iodine uptake test.
- Surgical Removal of Primary Tumor for Metastatic Breast Cancer
(Posted: 02/21/2012) - In this clinical trial, women with newly diagnosed metastatic breast cancer who are undergoing systemic therapy and whose disease does not progress within 16 weeks of starting that therapy will be randomly assigned to continue systemic therapy or to undergo surgical resection of their primary tumor.
- First-in-Humans Study of New Immunotherapy Agent
(Posted: 01/24/2012) - In this first-in-humans clinical trial of interleukin-15 (IL-15), patients with metastatic melanoma or metastatic renal cell cancer who have not benefited from other therapies will be given IL-15 by intravenous injection once a day for 12 days.
- Making Decisions about Cancer Prevention Medications for Breast Cancer
(Posted: 01/10/2012) - In this study, women age 35 or older who discuss the use of drugs called SERMs for breast cancer prevention with a health care provider will be asked to complete a questionnaire about their discussion and whether they have come to a decision about using a SERM for risk reduction, as well as a second questionnaire about their decision-making process.